News

02 February 2017

ABPI: UK pharmaceutical industry response to new Brexit White Paper

Mike Thompson, ABPI Chief Executive, has issued a statement in response to the publication of 'The United Kingdom’s Exit from, and New Partnership with, the European Union’ White Paper. For full details, go...

20 January 2017

MHRA Inspectorate Blog: Reference Safety Information II

This blog, written by Balall Naeem, follows up on queries raised in response to her first Reference Safety Information post. It also provides further guidance on areas of confusion identified by her presentation at the 2016 MHRA GCP Symposium...

20 January 2017

ABPI: response to BMJ article on US clinical trials with financial links to the pharmaceutical industry

The ABPI have responded to a new study recently published in the British Medical Journal (BMJ). This study suggests that clinical trials which are financially linked to the pharmaceutical industry have a 'bias in the evidence...

20 January 2017

ABPI: response to NICE - NHS England consultation on evaluating and funding new medicines

The ABPI has announced its response to the consultation by NICE and NHS England on evaluating and funding drugs and other health technologies. For further details, please...

20 January 2017

EMA: PRAC Meeting Highlights, 9th-12th January 2017

The EMA have published highlights from its January 2017 meeting of the Pharmacovigilance Risk Assessment Committee (PRAC): http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/01/news_detail_002677.jsp&mid=WC0b01ac05800...